Edition:
United Kingdom

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

12.43USD
17 May 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$12.43
Open
$12.40
Day's High
$12.68
Day's Low
$12.40
Volume
100,486
Avg. Vol
99,404
52-wk High
$14.96
52-wk Low
$9.07

Latest Key Developments (Source: Significant Developments)

ChemoCentryx Says Co Sold 4.8 Mln Shares Of Its Common Stock Pursuant To Its Equity Distribution Agreement With Piper Jaffray On March 25
Tuesday, 26 Mar 2019 

March 26 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX INC - ON MARCH 25, COMPANY SOLD 4.8 MILLION SHARES OF ITS COMMON STOCK PURSUANT TO ITS EQUITY DISTRIBUTION AGREEMENT WITH PIPER JAFFRAY & CO.CHEMOCENTRYX INC - SOLD COMMON STOCK AT A PRICE PER SHARE OF $11.40.  Full Article

ChemoCentryx Announces Withdrawal of Phase II-Based CMA Application for ANCA-Associated Vasculitis in Europe
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX ANNOUNCES WITHDRAWAL OF PHASE II-BASED CONDITIONAL MARKETING AUTHORIZATION (CMA) APPLICATION FOR ANCA-ASSOCIATED VASCULITIS IN EUROPE; PHASE III ADVOCATE TRIAL DATA RELEASE PLANNED FOR Q4 2019.CHEMOCENTRYX INC - IN LIGHT OF UPCOMING AVAILABILITY OF DATA FROM PIVOTAL PHASE III ADVOCATE TRIAL DECIDED TO WITHDRAW CMA OF AVACOPAN.CHEMOCENTRYX INC - DECIDED TO WITHDRAW APPLICATION CMA OF AVACOPAN FOR TREATMENT OF ANCA-ASSOCIATED VASCULITIS BASED ON PHASE II DATA.CHEMOCENTRYX INC - DECIDED NOT TO PROCEED WITH LIMITED PHASE II-BASED CMA IN EUROPE.CHEMOCENTRYX - EFFORTS TO NOW BE DIRECTED TO FILE INTEGRATED REGULATORY SUBMISSIONS IN 2020 WITH EMA, FDA FOR FULL (UNCONDITIONAL) MARKETING APPROVAL.  Full Article

Chemocentryx Files For Offer & Sell Up To $75 Mln Of Shares Of Stock
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX INC FILES FOR OFFER AND SELL UP TO $75.0 MILLION OF SHARES OF COMMON STOCK - SEC FILING.  Full Article

Chemocentryx - QTRLY Loss Per Share $0.22
Thursday, 8 Nov 2018 

ChemoCentryx Inc ::CHEMOCENTRYX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q3 REVENUE $9.0 MILLION.Q3 REVENUE VIEW $11.9 MILLION -- THOMSON REUTERS I/B/E/S.CHEMOCENTRYX - QTRLY LOSS PER SHARE $0.22.  Full Article

Vifor Pharma Increases Equity Investment In ChemoCentryx
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Vifor Pharma AG ::INCREASES EQUITY INVESTMENT IN CHEMOCENTRYX.INCREASES EQUITY STAKE IN CHEMOCENTRYX FROM 6.6% TO 21.2%.INCREASES EQUITY STAKE IN CHEMOCENTRYX FROM 6.6% TO 21.2%.  Full Article

Chemocentryx Inc QTRLY Loss Per Share $0.14
Thursday, 9 Aug 2018 

ChemoCentryx Inc ::CHEMOCENTRYX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 REVENUE $15 MILLION VERSUS I/B/E/S VIEW $14.1 MILLION.CHEMOCENTRYX - LAUNCH OF CLINICAL DEVELOPMENT OF AVACOPAN IN HIDRADENITIS SUPPURATIVA, ORPHAN DERMATOLOGICAL DISEASE, REMAINS ON TRACK FOR 2018.CHEMOCENTRYX - TARGETING Q4 2019 FOR RELEASING TOP-LINE DATA FROM ADVOCATE, EXPECT SUCCESSFUL TRIAL RESULTS WOULD BE BASIS OF NEW FDA DRUG APPLICATION.QTRLY LOSS PER SHARE $0.14.Q2 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.  Full Article

Chemocentryx reports Q3 revenue $9.0 million
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Chemocentryx Inc ::Chemocentryx reports third quarter 2017 financial results and recent highlights.Q3 revenue $9.0 million versus I/B/E/S view $9 million.Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​.Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​.Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​.Chemocentryx Inc - qtrly loss per share $0.13​.  Full Article

ChemoCentryx qtrly basic and diluted net loss per share $0.19
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Chemocentryx Inc :ChemoCentryx reports second quarter 2017 financial results and recent highlights.Q2 revenue $8.9 million versus $2.8 million.Qtrly basic and diluted net loss per share $0.19.  Full Article